MADE TO SAVE
An agile and patented advanced pharmaceutical manufacturing technology paving the way for rapid, low-cost and scalable domestic API production.
OUR AMERICAN DREAM
We believe in the power of American ingenuity and agility to deliver medicines that are safe, affordable and accessible to more people, in more places.
With multiple patents
in connection with our Spinning
Tube-in-Tube (STT®) continuous-flow reactors, our process decreases inefficiencies, reduces waste,
and lowers drug manufacturing costs in the United States. We are proudly part of the FDA's Emerging Technology Program as a selected innovation with scalable capabilities to quickly support the COVID-19 medicine shortage.
Agile and Scalable
Bright Path Labs has invested millions in R & D, to deliver an agile, advanced pharmaceutical manufacturing process that is scalable, high quality, low cost and safe. This is a process traditional
is unable to deliver with speed, consistency and scale
in the United States.
Bright Path is an independent firm and proudly embodies American ingenuity. In response to COVID-19 BPL has assembled a coalition of leading former pharma executives, chemists, biologists, researchers, and medical marketing experts to help accelerate the much-needed manufacturing of COVID-19 treatments, vaccines
and other medicines and orphan drugs for the American people.
Roughly 80 percent of the basic components used in U.S. drugs, known as active pharmaceutical ingredients (APIs), come from China and India. The COVID-19 crisis has quickly exposed significant gaps in the American drug supply.
The United States must change this paradigm and become medicine-independent.
Bright Path Labs (BPL) is positioned to immediately fill gaps in the drug supply chain in response to the COVID-19 pandemic; including the agile manufacturing of COVID-19 treatments or subsequently discovered vaccines and medicines to address future health challenges.
We have the physical and technical capacity for the agile research and development of advanced pharmaceutical manufacturing that is scalable, that helps us train a future workforce for research and is able to support Federal agencies to rapidly address drug shortages.